Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Lantheus, with nine holds and five buys among 14 analysts. The average 12-month price target is $108.11.
• Lantheus reported quarterly EPS of $1.55, beating the $1.30 consensus estimate, while revenue of $388.18 million also exceeded expectations and rose 2.7% year over year.
• Institutional investors and hedge funds own 99.06% of the stock, with several major firms recently increasing their positions; shares opened at $100.68, near the analyst target.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has received an average recommendation of "Hold" from the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $108.1111.

Several equities research analysts have issued reports on LNTH shares. CJS Securities cut Lantheus from a "market outperform" rating to a "market perform" rating in a research note on Tuesday, August 4th. Wall Street Zen cut shares of Lantheus from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 9th. Brookline Capital Markets cut Lantheus from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Leerink Partners set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. Finally, Mizuho reduced their price objective on shares of Lantheus from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Wednesday, July 29th.

Lantheus Stock Down 0.3%

LNTH stock opened at $100.68 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. Lantheus has a one year low of $49.67 and a one year high of $111.86. The firm's fifty day moving average is $104.25 and its 200 day moving average is $88.63. The firm has a market cap of $6.57 billion, a PE ratio of 24.32 and a beta of -0.03.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.57 EPS. On average, research analysts forecast that Lantheus will post 4.5 EPS for the current year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. M&T Bank Corp purchased a new position in shares of Lantheus in the 4th quarter valued at $370,950,000. Farallon Capital Management LLC grew its position in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider's stock valued at $361,199,000 after buying an additional 1,950,252 shares during the last quarter. Reinhart Partners LLC. increased its stake in Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider's stock valued at $177,437,000 after buying an additional 34,501 shares during the period. Dimensional Fund Advisors LP raised its position in Lantheus by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider's stock worth $94,202,000 after buying an additional 44,374 shares during the last quarter. Finally, Carmignac Gestion raised its position in Lantheus by 18.4% during the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider's stock worth $100,729,000 after buying an additional 206,000 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source